A clinically grounded guide to how BMT works, who qualifies, and what families in Jaipur need to know before making this life-changing decision.
By Apex Hospitals· Published 18th Sept, 2026
Thalassemia is an inherited blood disorder that affects how the body makes haemoglobin, and it exists on a spectrum. In thalassemia minor (or thalassemia trait), a person carries one faulty gene and is usually healthy, often unaware they're a carrier. In thalassemia intermedia, both genes are affected but the anaemia is milder and manageable without regular transfusions. In thalassemia major, both copies of the gene are severely defective, and the anaemia is severe enough to become apparent within the first two years of life.
This article is specifically about thalassemia major, because it's the form that makes regular blood transfusions a lifelong necessity, and the one form where a cure is now possible.
Every few weeks, thousands of children across India sit quietly in hospital chairs while blood drips slowly into their veins. For families living with thalassemia major, these transfusions are not a treatment, they are a lifeline. Yet each one carries risks: iron overload, alloimmunisation, and the relentless burden of lifelong hospital visits. The question that haunts every parent is simple: is there a cure?
The answer, increasingly, is yes, and it comes in the form of a bone marrow transplant (BMT), also called a haematopoietic stem cell transplant (HSCT). This article explains how BMT works for thalassemia, who is an ideal candidate, what the procedure involves, and what families seeking haemato-oncology and blood disorder care in Jaipur should realistically expect.
Thalassemia is an inherited blood disorder that affects how the body makes haemoglobin, the protein inside red blood cells that carries oxygen. It exists on a spectrum. In thalassemia minor (or thalassemia trait), a person carries one faulty gene and is usually healthy, often unaware they are even a carrier. In thalassemia intermedia, both genes are affected but the anaemia is milder and can often be managed without regular transfusions. In thalassemia major, both copies of the gene are severely defective, causing severe anaemia that becomes apparent within the first two years of life. This article focuses specifically on thalassemia major, since it's the form that makes lifelong transfusions necessary, and the one form where a cure is now possible.
Without treatment, children with thalassemia major develop progressive organ failure. Regular red blood cell transfusions, typically every 2–4 weeks, correct the anaemia but introduce a new problem: iron overload. Each unit of transfused blood deposits iron that the body cannot excrete. Over years, excess iron accumulates in the heart, liver, and endocrine glands, causing organ damage that can be fatal even with chelation therapy.
According to the World Health Organization, approximately 56,000 children are born each year with severe forms of thalassemia globally, with India accounting for the largest share. Rajasthan, with its high rates of consanguineous marriage in certain communities, carries a disproportionate burden. This makes access to curative therapy in cities like Jaipur especially critical.
A bone marrow transplant replaces a patient's diseased stem cells, the factory that produces defective red blood cells, with healthy stem cells from a compatible donor. Once engrafted, the donor stem cells begin producing normal haemoglobin, effectively eliminating the need for transfusions.
The procedure has three broad phases:
Conditioning: The patient receives high-dose chemotherapy, and sometimes low-dose radiation, to destroy the existing bone marrow and suppress the immune system so it does not reject the donor cells. This phase typically lasts 7–10 days.
Stem Cell Infusion: Healthy stem cells from the donor (harvested from bone marrow, peripheral blood, or umbilical cord blood) are infused intravenously, much like a blood transfusion. The cells migrate to the bone marrow cavities and begin engrafting.
Engraftment and Recovery: Over 2–4 weeks, the donor stem cells establish themselves and begin producing healthy blood cells. The patient is monitored closely in a sterile environment for infection, graft failure, and graft-versus-host disease (GvHD).
Successful engraftment means the patient's body now produces normal haemoglobin independently. Most patients who achieve stable engraftment are eventually transfusion-free, a functional cure.
How well a transplant works depends a lot on how healthy the patient is going into it, which is why doctors use a scoring system developed in Pesaro, Italy, so it's often called the Pesaro classification, to check this beforehand. It looks at three things: how consistently the patient has been getting iron-removal treatment (chelation), how enlarged the liver has become, and whether the liver has started to scar. Patients who score well on all three fall into the lowest-risk group, and they tend to do very well: survival rates above 90%, and most go on to live transfusion-free for good, when the donor is a fully matched brother or sister.
The key variables that influence success include:
Age: Transplants done in younger children, ideally before age 7, tend to succeed more often, mainly because there's been less time for iron to damage the organs.
How closely matched the donor is: A sibling who's a full match gives the best results. If there's no matching sibling, a matched donor found through a donor registry, or even a half-matched donor such as a parent, is increasingly a workable option.
Pre-transplant organ status: Well-managed iron levels and a liver in good shape make the whole process safer.
Not every child with thalassemia needs, or should have, a transplant. A haematologist and transplant specialist need to properly assess each case, but broadly, a good candidate:
Has thalassemia major, or a severe form of thalassemia intermedia that already needs regular transfusions
Is young — ideally under 14, though adults are considered individually
Has a donor available — a matched sibling is best, but unrelated or half-matched donors are increasingly an option
Is otherwise healthy enough that the heart, liver, and kidneys can handle the treatment
Has kept iron levels reasonably under control through regular chelation
Children with thalassemia trait (the mild, carrier form) or thalassemia intermedia who don't need regular transfusions usually aren't candidates, for them, the risks of a transplant outweigh the benefit.
Families in Rajasthan considering this path can seek evaluation through the haemato-oncology team at Apex Hospitals, which manages complex blood disorders including thalassemia across its Jaipur campuses.
Knowing roughly what lies ahead makes it easier to prepare, both emotionally and practically. A typical thalassemia BMT unfolds over several months, in five broad stages.
Before anything happens, the medical team runs a thorough set of checks, tissue-matching tests on the patient and any possible donors, tests on how well the heart and other organs are working, a blood test and a special MRI scan to measure how much iron has built up in the body, and screening for infections. This is also when the family sits down with the transplant team to talk through the risks, the benefits, and any alternatives.
If a brother or sister is donating, they'll either have bone marrow collected directly under general anaesthesia, or have stem cells collected from their blood after a few days of injections that boost stem cell numbers. If cord blood was saved at the sibling's birth and is a match, that can be used instead.
The patient is admitted to a specially controlled, infection-free unit. Over about 7 to 10 days, they receive high-dose chemotherapy to clear out the old, faulty bone marrow and prepare the body to accept new cells. Then, on what doctors call "Day 0," the donor's stem cells are given through a drip, much like a regular blood transfusion.
This is the most delicate stretch. With the old marrow gone and the new marrow not yet working, the patient has very little immunity, so the team keeps a close watch, using antibiotics, antifungal and antiviral medicines, and blood support as needed. Doctors confirm the new marrow has "taken" once a specific white blood cell count stays healthy for three days in a row.
After going home, the patient continues regular check-ups for months, watching for any sign of the donor cells reacting against the body (called graft-versus-host disease), infection, or the new marrow not fully taking hold. Medicines that suppress the immune system are slowly reduced. Blood tests track haemoglobin levels and check what percentage of blood cells are now coming from the donor rather than the patient's own — this tells the team how well the transplant has worked.
Once nearly all of the patient's blood cells are being made by the donor's stem cells and haemoglobin levels stay stable, the child is considered cured. The extra iron built up over years of transfusions doesn't disappear overnight — it clears gradually, often helped along by controlled blood removal, similar to donating blood, once the new marrow is making healthy blood on its own.
A bone marrow transplant isn't without risk, and families deserve a clear picture of what could go wrong.
Graft-versus-Host Disease (GvHD): Sometimes the new immune system sees the patient's own body as foreign and attacks it, usually the skin, gut, or liver. If this happens within the first 100 days, it's called acute GvHD; if it develops later and lingers, it's chronic. Newer medicines to suppress the immune system have made the severe form of this much less common than it used to be.
Graft Failure: In a small percentage of cases, the donor's stem cells either don't establish themselves or get rejected by the body. If this happens, a second transplant may be attempted.
Infections: For a few weeks after transplant, the patient has very little immune protection, which makes them vulnerable to bacterial, fungal, and viral infections. This is expected, and preventive medicines along with close monitoring are a standard part of care.
Strain on other organs: The high-dose chemotherapy used to prepare the body can be hard on the liver (a condition called veno-occlusive disease), cause painful mouth and gut sores (mucositis), and put temporary stress on the kidneys.
Fertility: The chemotherapy can affect the ability to have children later in life. This is worth discussing with the medical team before the transplant begins, especially for older children and teenagers, so that fertility preservation options can be considered in time.
These risks need to be weighed against what happens without a transplant: a lifetime of transfusions, gradually worsening iron overload, organ damage, and a shorter life expectancy. For a lower-risk patient with a fully matched sibling donor, the balance generally favours going ahead with the transplant.
Jaipur has emerged as a regional hub for haematology and transplant services in Rajasthan, reducing the need for families to travel to Delhi or Mumbai. When evaluating a centre for BMT, families should ask about:
The centre's annual BMT volume and thalassemia-specific transplant experience
Availability of a dedicated, HEPA-filtered BMT unit with positive pressure rooms
In-house pathology and HLA typing laboratory capabilities
Multidisciplinary support including nephrology, pulmonology, and internal medicine for peri-transplant complications
Empanelment under Ayushman Bharat and major insurance schemes to reduce financial burden
Post-transplant follow-up protocols and access to GvHD management
Apex Hospitals, NABH-accredited and operating since 1994, is empanelled under Ayushman Bharat and major TPA schemes. Its advanced ICU infrastructure — including a dedicated Advanced ICU with ECMO capability and a HOPE Tele-ICU Command Centre connecting 18 partner sites across Rajasthan — ensures that patients receive super-specialty monitoring throughout the transplant journey. The hospital's ICU and critical care team works in tandem with haematologists during the vulnerable post-transplant window.
Yes, in the majority of low-risk patients with a matched sibling donor, successful BMT results in transfusion independence and is considered a functional cure. Patients with full donor chimerism produce normal haemoglobin for life. Success rates exceed 85–90% in well-selected, younger patients at experienced centres.
Younger children — ideally under 7 years of age — have the best outcomes because they have had less cumulative iron overload and organ damage. However, transplants are performed in older children and selected adults, with outcomes evaluated individually based on organ function and donor availability.
Matched unrelated donors (from national and international registries) and haploidentical (half-matched) family donors are increasingly used. Outcomes with these alternatives have improved significantly with advances in HLA typing, conditioning regimens, and GvHD prophylaxis. Cord blood transplants are another option when a matched sibling cord blood unit was banked at birth.
The inpatient stay typically ranges from 4 to 8 weeks, covering the conditioning phase, stem cell infusion, and early engraftment monitoring. After discharge, frequent outpatient visits are required for 3–6 months, and the patient should remain close to the transplant centre during this period.
Once the transplant is successful and the patient no longer needs transfusions, iron overload gradually resolves. Therapeutic phlebotomy (periodic blood removal) is often used to accelerate iron clearance once haemoglobin levels are stable. Liver iron concentration is monitored via MRI to track progress.
If your child has thalassemia major and you want to understand whether bone marrow transplant is the right path, our haematology team at Apex Hospitals Jaipur is here to help you navigate every step.
Download Our App
Powered By Docfyn
